|
Gene: CFI |
Gene summary for CFI |
Gene summary. |
Gene information | Species | Human | Gene symbol | CFI | Gene ID | 3426 |
Gene name | complement factor I | |
Gene Alias | AHUS3 | |
Cytomap | 4q25 | |
Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | A8K3L0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3426 | CFI | PTC07 | Human | Thyroid | PTC | 2.90e-48 | 8.99e-01 | 0.2044 |
3426 | CFI | ATC09 | Human | Thyroid | ATC | 6.23e-04 | 2.93e-01 | 0.2871 |
3426 | CFI | ATC1 | Human | Thyroid | ATC | 1.59e-04 | 3.84e-01 | 0.2878 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CFI | SNV | Missense_Mutation | novel | c.1225N>A | p.His409Asn | p.H409N | protein_coding | tolerated(0.31) | benign(0) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CFI | SNV | Missense_Mutation | novel | c.958N>A | p.Asp320Asn | p.D320N | protein_coding | tolerated(0.2) | benign(0.041) | TCGA-AN-A0XV-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CFI | SNV | Missense_Mutation | rs189153845 | c.333N>C | p.Lys111Asn | p.K111N | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
CFI | SNV | Missense_Mutation | novel | c.1234C>G | p.Leu412Val | p.L412V | protein_coding | tolerated(0.39) | benign(0) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
CFI | SNV | Missense_Mutation | novel | c.1707A>C | p.Lys569Asn | p.K569N | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CFI | SNV | Missense_Mutation | rs758017357 | c.1315G>A | p.Ala439Thr | p.A439T | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CFI | SNV | Missense_Mutation | novel | c.351G>T | p.Lys117Asn | p.K117N | protein_coding | tolerated(0.53) | benign(0.01) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
CFI | SNV | Missense_Mutation | novel | c.1394N>G | p.Ser465Cys | p.S465C | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CFI | SNV | Missense_Mutation | rs754851037 | c.1366C>T | p.Arg456Cys | p.R456C | protein_coding | tolerated(0.09) | possibly_damaging(0.684) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CFI | SNV | Missense_Mutation | rs777190530 | c.1190N>A | p.Arg397His | p.R397H | protein_coding | tolerated(0.54) | benign(0.005) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3426 | CFI | ENZYME, DRUGGABLE GENOME, PROTEASE | TGFBETA1 | 17320177 |
Page: 1 |